American Journal of Cardiology
Volume 103, Issue 4 , Pages 437-441 , 15 February 2009

Comparison of Effects of Rosuvastatin (10 mg) Versus Atorvastatin (40 mg) on Rho Kinase Activity in Caucasian Men With a Previous Atherosclerotic Event

Received 31 July 2008 ,Revised 7 October 2008 ,Accepted 7 October 2008.

References 

  1. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322–334
  2. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, et al Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000;101:2030–2033
  3. Liao JK. Rho-kinase: a potential link between hypercholesterolemia and abnormal vascular smooth muscle contraction. Circ Res. 2006;99:238–239
  4. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266–24271
  5. Seasholtz TM, Majumdar M, Kaplan DD, Brown JH. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res. 1999;84:1186–1193
  6. Bolz SS, Vogel L, Sollinger D, Derwand R, de Wit C, Loirand G, et al. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation. 2003;107:3081–3087
  7. Wojciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol. 1999;145:1293–1307
  8. Miyata K, Shimokawa H, Kandabashi T, Higo T, Morishige K, Eto Y, et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol. 2000;20:2351–2358
  9. Ito T, Ikeda U, Shimpo M, Ohki R, Takahashi M, Yamamoto K, et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther. 2002;16:121–126
  10. Ishibashi T, Nagata K, Ohkawara H, Sakamoto T, Yokoyama K, Shindo J, et al. Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes. Biochim Biophys Acta. 2002;1590:123–130
  11. Nakakuki T, Ito M, Iwasaki H, Kureishi Y, Okamoto R, Moriki N, et al. Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol. 2005;25:2088–2093
  12. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation. 2005;111:3261–3268
  13. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells (Role of geranylgeranylation and Rho proteins). Circ Res. 1998;83:683–690
  14. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:21926–21931
  15. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:556–562
  16. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002;105:1756–1759
  17. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl. 2003;4:9–14
  18. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995;346:467–471
  19. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582–587
  20. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152–160
  21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  22. Amano M, Mukai H, Ono Y, Chihara K, Matsui T, Hamajima Y, et al. Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Science. 1996;271:648–650
  23. Liu PY, Chen JH, Lin LJ, Liao JK. Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol. 2007;49:1619–1624
  24. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, et al. Rho Kinase Inhibition Improves Endothelial Function in Human Subjects With Coronary Artery Disease. Circ Res. 2006;99:1426–1432
  25. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  26. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004;24:1842–1847
  27. Jialal D, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933–1935

 This study was supported, in part, by grants from the National Institutes of Health; Dr. Liao was supported by grant HL052233, and Dr. Ganz was supported by grant PO1 HL-48743. Dr. Rawlings was supported by the the Sarnoff Cardiovascular Research Foundation. Dr. Nohria was supported by the American Heart Association, Northeast Affiliate Scientist Development Award 0335439T and the Doris Duke Cardiovascular Foundation. Dr. Liu was supported by the National Health Research Institute and Cardiovascular Research Center of National Cheng Kung Unversity, Tainan, Taiwan. Dr. Creager is the Simon C. Fireman Scholar of Medicine at Brigham and Women's Hospital.

 Drs. Nohria and Ganz have research grant support from Pfizer, Inc. Dr. Liao is a consultant for Merck, Pfizer, AstraZeneca, Boehringer Ingelheim, and Asahi-Kasei Pharmaceuticals and receives research support from Pfizer, AstraZeneca, and Boehringer Ingelheim. Dr. Liao is also on the speaker bureau for Merck, Pfizer, AstraZeneca, and Boehringer Ingelheim. Dr. Creager received support from Merck.

PII: S0002-9149(08)01878-X

doi: 10.1016/j.amjcard.2008.10.008

American Journal of Cardiology
Volume 103, Issue 4 , Pages 437-441 , 15 February 2009

Article Tools

* Image Usage & Resolution